Another recent study performed on EGFR-mutant NSCLC patients treated in first-line with osimertinib confirmed a high-rate of response to treatment: in the group of patients treated with 160 mg osimertinib, the ORR was 87%, with a PFS of 19.3 months [331]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.